PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced…

By L. Paz-Ares, F. de Marinis, M. Dediu, Michael Thomas, J. Pujol, P. Bidoli, O. Molinier, T. Sahoo, E. Laack, M. Reck and 7 more. Journal of Clinical Oncology, 2013

601 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/68d4aa97f652b3d34112a0ca1036144dded45c42

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. K. Kerr
2. M. Hellmann

In Pulmonary and Respiratory Medicine

1. B. Chan
2. B. Hughes

Citations in the corpus

• Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. (2016, background): “Nine trials reported specifically on patients who had stable disease or experienced response after four to six cycles (maintenance).(7,8,33-40) There were 22 trials of second- and third-line therapies; two reported on the treatment of patients with ALK-positive tumors; none of these 22 trials requir”
• Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018, background): “A large phase III randomised trial of continuation maintenance with pemetrexed versus placebo after four induction cycles of cisplatin plus pemetrexed ChT demonstrated a PFS and OS improvement in patients with a PS 0–1, confirmed at longterm follow-up [129, 130].”
• Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial (2018, background): “Our study is unique in a number of ways when compared with similar, recently published findings: (1) only radiation, primarily SAbR, was used as local therapy with hypofractionation for primary disease as needed, with no patients undergoing surgery; (2) all disease in patients on the consolidative l”
• Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. (2015, background): “This distinction alone allows for a more tailored selection of cytotoxic chemotherapy in advanced NSCLC without a driver mutation, as seen with enhanced efficacy with pemetrexed in adenocarcinoma (14,15) or the toxicity concerns of bevacizumab in patients with squamous histology (16).”
• Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer (2018, unknown): “Because EGFR mutations are detected mostly in patients with an adenocarcinoma or non-squamous histology, the optimum regimen might be pemetrexed and platinum combination treatment [81], followed by maintenance pemetrexed for patients who did not suffer from disease progression [48, 82].”